502 related articles for article (PubMed ID: 11726322)
41. Expression of cyclins A, D2 and D3 in individual normal mitogen stimulated lymphocytes and in MOLT-4 leukemic cells analyzed by multiparameter flow cytometry.
Gong J; Bhatia U; Traganos F; Darzynkiewicz Z
Leukemia; 1995 May; 9(5):893-9. PubMed ID: 7769853
[TBL] [Abstract][Full Text] [Related]
42. Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium.
Chae SW; Song JJ; Suh HK; Jung HH; Lim HH; Hwang SJ
Laryngoscope; 2000 Nov; 110(11):1898-901. PubMed ID: 11081606
[TBL] [Abstract][Full Text] [Related]
43. Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1.
Kolar Z; Flavell JR; Ehrmann J; Rihakova P; Macak J; Lowe D; Crocker J; Vojtesek B; Young LS; Murray PG
J Pathol; 2000 Apr; 190(5):604-12. PubMed ID: 10727987
[TBL] [Abstract][Full Text] [Related]
44. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features.
Møller MB; Nielsen O; Pedersen NT
Am J Clin Pathol; 2001 Mar; 115(3):404-12. PubMed ID: 11242797
[TBL] [Abstract][Full Text] [Related]
45. Exploitation of a non-apoptotic caspase to regulate the abundance of the cdkI p27(KIP1) in transformed lymphoid cells.
Frost V; Al-Mehairi S; Sinclair AJ
Oncogene; 2001 May; 20(22):2737-48. PubMed ID: 11420686
[TBL] [Abstract][Full Text] [Related]
46. D-type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy.
Bartkova J; Rajpert-de Meyts E; Skakkebaek NE; Bartek J
J Pathol; 1999 Apr; 187(5):573-81. PubMed ID: 10398124
[TBL] [Abstract][Full Text] [Related]
47. CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Clin Exp Med; 2016 Aug; 16(3):317-32. PubMed ID: 26003188
[TBL] [Abstract][Full Text] [Related]
48. Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo.
Zhang W; Bergamaschi D; Jin B; Lu X
Blood; 2005 May; 105(9):3691-8. PubMed ID: 15665120
[TBL] [Abstract][Full Text] [Related]
49. [Lymphocyte subpopulations determined by flow cytometry in chronic type B lymphatic leukemia].
Kvasnicka J; Kruzík P; Cmunt E; Neurwirtová R
Cas Lek Cesk; 1994 Aug; 133(16):506-10. PubMed ID: 7923329
[TBL] [Abstract][Full Text] [Related]
50. Cell cycle effects of IL-10 on malignant B-1 cells.
Yen Chong S; Lin YC; Czarneski J; Zhang M; Coffman F; Kashanchi F; Raveche E
Genes Immun; 2001 Aug; 2(5):239-47. PubMed ID: 11528515
[TBL] [Abstract][Full Text] [Related]
51. Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL.
Halina A; Artur P; Barbara MK; Joanna S; Anna D
Folia Histochem Cytobiol; 2010 Dec; 48(4):534-41. PubMed ID: 21478095
[TBL] [Abstract][Full Text] [Related]
52. Immunobiology of chronic lymphocytic leukemia.
Freedman AS
Hematol Oncol Clin North Am; 1990 Apr; 4(2):405-29. PubMed ID: 2182599
[TBL] [Abstract][Full Text] [Related]
53. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways.
Bogner C; Schneller F; Hipp S; Ringshausen I; Peschel C; Decker T
Exp Hematol; 2003 Mar; 31(3):218-25. PubMed ID: 12644019
[TBL] [Abstract][Full Text] [Related]
54. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis.
Büssing A; Stein GM; Stumpf C; Schietzel M
Anticancer Res; 1999; 19(5B):3953-9. PubMed ID: 10628337
[TBL] [Abstract][Full Text] [Related]
55. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
Wang P; Pavletic ZS; Joshi SS
Leuk Lymphoma; 2002 Sep; 43(9):1827-35. PubMed ID: 12685840
[TBL] [Abstract][Full Text] [Related]
56. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
57. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Durrieu F; Geneviève F; Arnoulet C; Brumpt C; Capiod JC; Degenne M; Feuillard J; Garand R; Kara-Terki A; Kulhein E; Maynadié M; Ochoa-Noguera ME; Plesa A; Roussel M; Eghbali H; Truchan-Graczyk M; de Carvalho Bittencourt M; Feugier P; Béné MC
Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
[TBL] [Abstract][Full Text] [Related]
58. Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target.
Decker T; Hipp S; Hahntow I; Schneller F; Peschel C
Br J Haematol; 2004 Apr; 125(2):141-8. PubMed ID: 15059135
[TBL] [Abstract][Full Text] [Related]
59. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression.
Parada Y; Banerji L; Glassford J; Lea NC; Collado M; Rivas C; Lewis JL; Gordon MY; Thomas NS; Lam EW
J Biol Chem; 2001 Jun; 276(26):23572-80. PubMed ID: 11323429
[TBL] [Abstract][Full Text] [Related]
60. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C
Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
